30 Jun 2011

The UK's National Institute for Health and Clinical Excellence (NICE) has continued its decision of not approving erlotinib for treating locally advanced or metastatic non-small-cell lung cancer in patients who have stable disease following platinum-based chemotherapy.

Please click here to read the 'Medical News Today' article in full.